CRONNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Cronos Group Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.25+0.04 (+1.25%)
Close on Oct 19, 2026
- Market cap
- $1.22B
- P/E (TTM)
- 16.3
- Dividend yield
- –
Share price
+$0.76 (+30.52%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Cronos Group Inc. grew revenue 37.5% to $179.09M over the twelve months to Jun 30, 2026. Free cash flow was $49.82M.
Revenue
$179.09M
+37.5% vs. a year earlier
Operating income
-$2.43M
TTM Q2 2026
Free cash flow
$49.82M
TTM Q2 2026
EPS, diluted
$0.20
+300.0% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.22B
- P/E ratio
- 16.3
- Price to sales
- 6.81
- Price to book
- 1.14
- Dividend yield
- –
- Free cash flow yield
- 4.09%
Fundamentals
- Revenue
- $179.09M
- Net income
- $69.98M
- EPS, diluted
- $0.20
- Free cash flow
- $49.82M
- Book value per share
- $2.85
- Diluted shares
- 375M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
$179.09M+37.5% YoY
Gross profit
$82.13M+92.5% YoY
Operating income
-$2.43M
Net income
$69.98M+278.5% YoY
EPS, diluted
$0.20+300.0% YoY
Free cash flow
$49.82M
Reported periodTrailing twelve months